An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- Conditions
- Large B-Cell Lymphoma
- Interventions
- Registration Number
- NCT06047080
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 1130
- Previously untreated participants with CD20-positive LBCL
- Ability to provide tumor tissue
- International prognostic index (IPI) score 2-5
- Eastern cooperative oncology group (ECOG) performance status of 0, 1, or 2
- At least one bi-dimensionally measurable lesion, defined as > 1.5 cm in its longest dimension as measured by CT or MRI
- Left ventricular ejection fraction (LVEF) >/=50% on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram (ECHO)
- Adequate hematologic function
- Negative HIV test at screening with exceptions as defined by the protocol
- Negative SARS-CoV-2 antigen or PCR test
- Contraindication to any of the individual components of Pola-R-CHP or glofitamab, including prior receipt of anthracyclines, or history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, or known sensitivity or allergy to murine products
- Prior solid organ transplantation
- Participants receiving systemic immunosuppressive agent such as, but not limited to cyclosporin, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 4 weeks prior to first dose of study treatment
- Current Grade > 1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease
- History of indolent lymphoma (e.g., Follicular Lymphoma, Marginal Zone Lymphoma, Waldenstrom macroglobulinemia)
- Current diagnosis of the following: Follicular lymphoma grade 3B; transformations of indolent B-cell lymphomas (e.g., de novo transformed follicular lymphoma); mediastinal grey zone lymphoma; primary mediastinal (thymic) large B-cell lymphoma; Burkitt lymphoma; primary large B-cell lymphoma of immune-privileged sites (encompassing primary diffuse large B-cell lymphoma of the CNS, primary large B-cell lymphoma of the vitreoretina and primary large B-cell lymphoma of the testis); primary effusion DLBCL; and primary cutaneous DLBCL, leg type
- Primary or secondary CNS lymphoma at the time of recruitment or history of CNS lymphoma
- Prior treatment with systemic immunotherapeutic agents
- Prior use of any monoclonal antibody for the purposes of treating cancer within 3 months of the start of Cycle 1
- Any investigational therapy for the purposes of treating cancer within 28 days prior to the start of Cycle 1
- Prior radiotherapy to the mediastinal/pericardial region
- Prior therapy for LBCL, with the exception of corticosteriods
- Corticosteroid use > 30 mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control
- History of other malignant or non-malignant diseases that could affect compliance with the protocol or interpretation of results
- Significant or extensive history of cardiovascular disease
- Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
- Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
- Known or suspected chronic active Epstein-Barr viral infection
- Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
- Active autoimmune disease requiring treatment
- Clinically significant liver disease
- Live, attenuated vaccine within 4 weeks before study treatment infusion on Day 1 of Cycle 1 or anticipation that such a live, attenuated vaccine will be required during the study. Live vaccines during the study and until participants B cells recover are prohibited
- Any active infection within 7 days prior to Cycle 1 Day 1 that would impact participant safety
- Suspected active or latent tuberculosis
- Positive test results for chronic hepatitis B infection, hepatitis C, or the human T-lymphotropic virus type 1 (HTLV-1)
- History of progressive multifocal leukoencephalopathy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Glofitamab + Pola-R-CHP Glofitamab Participants will receive glofitamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP). Glofitamab + Pola-R-CHP Polatuzumab vedotin Participants will receive glofitamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP). Glofitamab + Pola-R-CHP Rituximab Participants will receive glofitamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP). Glofitamab + Pola-R-CHP Cyclophosphamide Participants will receive glofitamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP). Glofitamab + Pola-R-CHP Doxorubicin Participants will receive glofitamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP). Glofitamab + Pola-R-CHP Prednisone Participants will receive glofitamab in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP). Pola-R-CHP Polatuzumab vedotin Participants will receive Pola-R-CHP. Pola-R-CHP Rituximab Participants will receive Pola-R-CHP. Pola-R-CHP Cyclophosphamide Participants will receive Pola-R-CHP. Pola-R-CHP Doxorubicin Participants will receive Pola-R-CHP. Pola-R-CHP Prednisone Participants will receive Pola-R-CHP.
- Primary Outcome Measures
Name Time Method Progression-free survival (PFS) as determined by Independent Review Facility (IRF) From randomization to the first occurrence of disease progression or relapse, or death due to any cause, whichever occurs first (up to approximately 65 months)
- Secondary Outcome Measures
Name Time Method PFS as determined by the investigator From randomization to the first occurrence of disease progression or relapse or death from any cause, whichever occurs first (up to approximately 65 months) PFS as determined by the investigator and IRF for participants with international prognostic index (IPI) 3-5 From randomization to the first occurrence of disease progression or relapse or death from any cause, whichever occurs first (up to 65 months) Event-free survival efficacy causes (EFSeff) From randomization to the earliest occurrence of disease progression or relapse; death due to any cause; initiation of new anti-lymphoma treatment; or positive biopsy for residual disease after treatment completion (up to approximately 65 months) Complete response (CR) rate At the end of treatment (up to approximately 65 months) Objective response rate (ORR) At treatment completion or discontinuation (up to approximately 65 months) Overall survival (OS) From randomization to death from any cause (up to approximately 65 months) Duration of response (DOR) From the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to approximately 65 months) Duration of complete response (DOCR) From the first occurrence of a documented complete response (CR) to disease progression or death, whichever occurs first (up to approximately 65 months) Disease-free survival (DFS) From a documented CR at the end of treatment to disease progression or death, whichever occurs first (up to approximately 65 months) Serum concentration of glofitamab Up to approximately 65 months Incidence of anti-drug antibodies (ADAs) Baseline up to approximately 65 months Proportion of participants experiencing a clinically meaningful improvement in physical functioning and fatigue (EORTC QLQ-C30) and lymphoma symptoms (FACT-Lym LymS) Up to approximately 65 months Time to deterioration in physical functioning and fatigue (EORTC QLQ-C30) and lymphoma symptoms (FACT-Lym LymS) Up to approximately 65 months Percentage of Participants with Adverse Events (AEs) From randomization to the end of study (up to approximately 65 months)
Trial Locations
- Locations (268)
Alaska Oncology & Hematology, LLC
🇺🇸Anchorage, Alaska, United States
Kaiser Permanente - Anaheim (E. La Palma)
🇺🇸Anaheim, California, United States
University of California, San Francisco-Fresno
🇺🇸Clovis, California, United States
City of Hope National Medical Center
🇺🇸Duarte, California, United States
City of Hope - Lennar Foundation Cancer Center
🇺🇸Irvine, California, United States
Scripps Clinic Torrey Pines
🇺🇸La Jolla, California, United States
Valkyrie Clinical Trials
🇺🇸Los Angeles, California, United States
UCLA Jonsson Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Kaiser Permanente - Oakland
🇺🇸Oakland, California, United States
Kaiser Permanente - Roseville
🇺🇸Roseville, California, United States
Kaiser Permanente - San Francisco (2238 Geary)
🇺🇸San Francisco, California, United States
Kaiser Permanente - Santa Clara
🇺🇸Santa Clara, California, United States
Stanford Univ School of Med
🇺🇸Stanford, California, United States
Kaiser Permanente Medical Ctr
🇺🇸Vallejo, California, United States
Kaiser Permanente - Walnut Creek
🇺🇸Walnut Creek, California, United States
University of Colorado Cancer Center
🇺🇸Aurora, Colorado, United States
Rocky Mountain Cancer Center - Denver
🇺🇸Littleton, Colorado, United States
Yale University School Of Medicine
🇺🇸New Haven, Connecticut, United States
Medstar Franklin Square Medical Center
🇺🇸Washington, District of Columbia, United States
Miami Cancer Institute of Baptist Health, Inc.
🇺🇸Miami, Florida, United States
Memorial Cancer Institute at Memorial West
🇺🇸Pembroke Pines, Florida, United States
Hawaii Cancer Care
🇺🇸Honolulu, Hawaii, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
🇺🇸Chicago, Illinois, United States
NorthShore Center for Advanced Imaging
🇺🇸Evanston, Illinois, United States
Illinois Cancer Care
🇺🇸Peoria, Illinois, United States
Springfield Clinic
🇺🇸Springfield, Illinois, United States
University of Iowa
🇺🇸Iowa City, Iowa, United States
Ascension Via Christi Research
🇺🇸Wichita, Kansas, United States
Ochsner Medical Center
🇺🇸New Orleans, Louisiana, United States
Louisiana State University Health Sciences Center
🇺🇸Shreveport, Louisiana, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Boston Medical Center
🇺🇸Boston, Massachusetts, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Henry Ford Health System
🇺🇸Novi, Michigan, United States
M Health Fairview University of Minnesota Medical Center
🇺🇸Minneapolis, Minnesota, United States
St. Luke's Hospital
🇺🇸Chesterfield, Missouri, United States
University of Missouri Health Care
🇺🇸Columbia, Missouri, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
St. Vincent Frontier Cancer Center
🇺🇸Billings, Montana, United States
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
MSKCC at Basking Ridge
🇺🇸Basking Ridge, New Jersey, United States
Astera Cancer Care East Brunswick
🇺🇸East Brunswick, New Jersey, United States
MSK Monmouth
🇺🇸Middletown, New Jersey, United States
MSK Bergen
🇺🇸Montvale, New Jersey, United States
Montefiore Medical Center - Montefiore Medical Park
🇺🇸Bronx, New York, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States
New York Cancer & Blood Specialists
🇺🇸Bronx, New York, United States
NYU Langone Hospital?Brooklyn
🇺🇸Brooklyn, New York, United States
MSK Commack
🇺🇸Commack, New York, United States
Memorial Sloan Kettering Cancer Center
🇺🇸Harrison, New York, United States
NYU Long Island Hospital
🇺🇸Mineola, New York, United States
New York Cancer and Blood Specialists - New Hyde Park
🇺🇸New Hyde Park, New York, United States
New York University Medical Center PRIME
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center David H Koch Center for Cancer Care
🇺🇸New York, New York, United States
Weill Cornell Medical College-New York Presbyterian Hospital
🇺🇸New York, New York, United States
New York Cancer and Blood Specialists-Central Park Hematology & Oncology
🇺🇸New York, New York, United States
North Shore Hematology Oncology Association PC
🇺🇸Shirley, New York, United States
MSK Nassau
🇺🇸Uniondale, New York, United States
Instituto Alexander Fleming
🇦🇷Buenos Aires, Argentina
University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Levine Cancer Institute
🇺🇸Charlotte, North Carolina, United States
Oncology Hematology Care Inc - Cincinnati - USOR
🇺🇸Cincinnati, Ohio, United States
Willamette Valley Cancer Insitute and Research Center
🇺🇸Springfield, Oregon, United States
Kimmel Cancer Center Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
West Penn Hospital
🇺🇸Pittsburgh, Pennsylvania, United States
Avera Cancer Institute
🇺🇸Sioux Falls, South Dakota, United States
Greco-Hainesworth Tennessee Oncology Centers for Research
🇺🇸Chattanooga, Tennessee, United States
West Cancer Center & Research Institute
🇺🇸Germantown, Tennessee, United States
SCRI Oncology Partners
🇺🇸Nashville, Tennessee, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
🇺🇸Dallas, Texas, United States
Texas Oncology
🇺🇸Fort Worth, Texas, United States
Harris Health System Smith Clinic
🇺🇸Houston, Texas, United States
O'Quinn Medical Tower at McNair Campus
🇺🇸Houston, Texas, United States
USOR - Texas Oncology - San Antonio Northeast
🇺🇸San Antonio, Texas, United States
University of Vermont
🇺🇸Burlington, Vermont, United States
Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
Virginia Oncology Associates
🇺🇸Newport News, Virginia, United States
Swedish Cancer Institute - Edmonds Campus
🇺🇸Edmonds, Washington, United States
Swedish Medical Center
🇺🇸Seattle, Washington, United States
University of Washington - Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
West Virginia University
🇺🇸Morgantown, West Virginia, United States
Univ of Wisconsin Hosp & Clin
🇺🇸Madison, Wisconsin, United States
FUNDALEU
🇦🇷Buenos Aires, Argentina
Hospital Aleman de Buenos Aires
🇦🇷Buenos Aires, Argentina
Sanatorio Allende
🇦🇷Cordoba, Argentina
Hospital Austral
🇦🇷Pilar, Argentina
Concord Repatriation General Hospital
🇦🇺Concord, New South Wales, Australia
Prince of Wales Hospital- Department of Hematology
🇦🇺Randwick, New South Wales, Australia
Townsville Hospital
🇦🇺Douglas, Queensland, Australia
Princess Alexandra Hospital Woolloongabba
🇦🇺Woolloongabba, Queensland, Australia
Flinders Medical Centre
🇦🇺Bedford Park, South Australia, Australia
Royal Hobart Hospital
🇦🇺Hobart, Tasmania, Australia
Eastern Health
🇦🇺Box Hill, Victoria, Australia
St Vincent's Hospital Melbourne
🇦🇺Fitzroy, Victoria, Australia
Barwon Health
🇦🇺Geelong, Victoria, Australia
Peter Maccallum Cancer Centre
🇦🇺Melbourne, Victoria, Australia
Second Affiliated Hospital of Third Military Medical University
🇨🇳Chongqing, China
Sir Charles Gairdner Hospital
🇦🇺Nedlands, Western Australia, Australia
Institut Jules Bordet
🇧🇪Anderlecht, Belgium
UZ Brussel
🇧🇪Brussel, Belgium
UZ Antwerpen
🇧🇪Edegem, Belgium
UZ Gent
🇧🇪Gent, Belgium
AZ Groeninge
🇧🇪Kortrijk, Belgium
CHU Sart-Tilman
🇧🇪Liège, Belgium
Hospital Erasto Gaertner
🇧🇷Curitiba, Paraná, Brazil
Instituto D'Or Pesquisa e Ensino
🇧🇷Sao Paulo, São Paulo, Brazil
Hospital das Clinicas - FMUSP, Oncologia
🇧🇷Sao Paulo, São Paulo, Brazil
Eastern Health - General Hospital
🇨🇦St. John's, Newfoundland and Labrador, Canada
Queen Elizabeth II Health Sciences Centre
🇨🇦Halifax, Nova Scotia, Canada
Royal Victoria Regional Health Centre
🇨🇦Barrie, Ontario, Canada
William Osler Health Centre - Brampton Civic Hospital
🇨🇦Brampton, Ontario, Canada
The Ottawa Hospital - General Campus
🇨🇦Ottawa, Ontario, Canada
Health Sciences North
🇨🇦Sudbury, Ontario, Canada
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM)
🇨🇦Montreal, Quebec, Canada
CHA Hopital de I enfant-Jesus
🇨🇦Quebec City, Quebec, Canada
Centre Integre Universitaire de Sante et de Services Sociaux de la Mauricie-et-du-Centre-du-Quebec
🇨🇦Trois-rivieres, Quebec, Canada
Beijing Cancer Hospital
🇨🇳Beijing, China
Peking University Third Hospital
🇨🇳Beijing, China
The First Hospital of Jilin University
🇨🇳Changchun City, China
Hunan Cancer Hospital
🇨🇳Changsha CITY, China
West China Hospital, Sichuan University
🇨🇳Chengdu, China
Sichuan Provincial People's Hospital
🇨🇳Chengdu, China
Fujian Cancer Hospital
🇨🇳Fuzhou, China
Southern Medical University Nanfang Hospital
🇨🇳Guangdong Province Guangzhou City, China
Sun yat-sen University Cancer Center
🇨🇳Guangzhou, China
Zhujiang Hospital, Southern Medical University
🇨🇳Guangzhou, China
Harbin Medical University Cancer Hospital
🇨🇳Harbin, China
Anhui Province Cancer Hospital
🇨🇳Hefei City, China
Shandong Cancer Hospital
🇨🇳Jinan, China
Jiangxi Cancer Hospital
🇨🇳Nanchang City, China
Jiangsu Cancer Hospital
🇨🇳Nanjing City, China
Guangxi Cancer Hospital of Guangxi Medical University
🇨🇳Nanning, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai City, China
Shengjing Hospital of China Medical University
🇨🇳Shenyang City, China
First Hospital of China Medical University
🇨🇳Shenyang, China
First Affiliated Hospital of Soochow University
🇨🇳Suzhou, China
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
🇨🇳Tianjin City, China
Tianjin Cancer Hospital
🇨🇳Tianjin, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan City, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan City, China
The First Affiliated Hospital of Xiamen University
🇨🇳Xiamen, China
The First Affiliated Hospital of Zhengzhou University
🇨🇳Zhengzhou, China
Aalborg Universitetshospital
🇩🇰Aalborg, Denmark
Aarhus Universitetshospital Skejby
🇩🇰Aarhus N, Denmark
Regionshospitalet Gødstrup
🇩🇰Herning, Denmark
CHRU de Lille - Hopital Claude Huriez
🇫🇷Lille, France
Hospices Civils de Lyon
🇫🇷Lyon, France
Institut Paoli Calmettes
🇫🇷Marseille, France
CHU Montpellier
🇫🇷Montpellier, France
CHU de Nantes - Hotel Dieu
🇫🇷Nantes, France
CHU de Bordeaux
🇫🇷Pessac, France
CHU DE RENNES - CHU Pontchaillou
🇫🇷Rennes, France
Centre Henri Becquerel
🇫🇷Rouen, France
CHU Strasbourg Hpital Hautepierre
🇫🇷Strasbourg, France
IUCT Oncopole
🇫🇷Toulouse, France
Charité Universitätsmedizin Berlin
🇩🇪Berlin, Germany
Staedisches Klinikum Brandenburg
🇩🇪Brandenburg an der Havel, Germany
Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III
🇩🇪Chemnitz, Germany
Universitätsklinikum Düsseldorf
🇩🇪Düsseldorf, Germany
Universitätsklinikum Erlangen, Medizinische Klinik 5, Hämatologie und Internistische Onkologie
🇩🇪Erlangen, Germany
Universitätsklinikum Essen
🇩🇪Essen, Germany
Universitätsklinikum Frankfurt
🇩🇪Frankfurt, Germany
UKE Universitätsklinikum Hamburg-Eppendorf
🇩🇪Hamburg, Germany
Westpfalz-Klinikum GmbH
🇩🇪Kaiserslautern, Germany
Städtisches Krankenhaus Kiel GmbH
🇩🇪Kiel, Germany
Universitätsklinikum Köln
🇩🇪Koeln, Germany
Universitaetsklinikum Schleswig Holstein - Campus Luebeck
🇩🇪Luebeck, Germany
Otto von Guericke Uni Magdeburg Uniklinik
🇩🇪Magdeburg, Germany
Klinikum rechts der Isar der TU München, III. Medizinische Klinik
🇩🇪München, Germany
Universitätsklinikum Münster
🇩🇪Münster, Germany
Klinikum Ernst von Bergman
🇩🇪Potsdam, Germany
Universitaet Rostock, Zentrum Innere Medizin
🇩🇪Rostock, Germany
Klinikum Stuttgart Katharinenhospital
🇩🇪Stuttgart, Germany
Universitätsklinikum Ulm
🇩🇪Ulm, Germany
Universitätsklinikum Würzburg
🇩🇪Würzburg, Germany
Istituto Nazionale Tumori Irccs Fondazione g. Pascale
🇮🇹Napoli, Campania, Italy
Policlinico S.Orsola-Malpighi
🇮🇹Bologna, Emilia-Romagna, Italy
A.O. Universitaria Policlinico Di Modena
🇮🇹Modena, Emilia-Romagna, Italy
A.O. Universitaria S. Martino Di Genova
🇮🇹Genova, Liguria, Italy
Asst Papa Giovanni Xxiii
🇮🇹Bergamo, Lombardia, Italy
Fond. IRCCS Istituto Nazionale Tumori
🇮🇹Milano, Lombardia, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano, Lombardia, Italy
A. O. U. Policlinico G. Rodolico
🇮🇹Catania, Sicilia, Italy
USL 4 di Prato - Nuovo Ospeale di Prato
🇮🇹Prato, Toscana, Italy
Ospedale San Bortolo
🇮🇹Vicenza, Veneto, Italy
Anjo Kosei Hospital
🇯🇵Aichi, Japan
Aichi Cancer Center
🇯🇵Aichi, Japan
Nagoya University Hospital
🇯🇵Aichi, Japan
Chiba Cancer Center
🇯🇵Chiba, Japan
National Cancer Center Hospital East
🇯🇵Chiba, Japan
National Hospital Organization Kyushu Cancer Center
🇯🇵Fukuoka, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Gifu University Hospital
🇯🇵Gifu, Japan
Hokkaido University Hospital
🇯🇵Hokkaido, Japan
Kobe City Medical Center General Hospital
🇯🇵Hyogo, Japan
Kanagawa Cancer Center
🇯🇵Kanagawa, Japan
Tokai University Hospital
🇯🇵Kanagawa, Japan
University Hospital Kyoto Prefectural University of Medicine
🇯🇵Kyoto, Japan
Tohoku University Hospital
🇯🇵Miyagi, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Osaka Metropolitan University Hospital
🇯🇵Osaka, Japan
Kansai Medical University Hospital
🇯🇵Osaka, Japan
Kindai University Hospital
🇯🇵Osaka, Japan
Shimane University Hospital
🇯🇵Shimane, Japan
National Cancer Center Hospital
🇯🇵Tokyo, Japan
Komagome Hospital
🇯🇵Tokyo, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Keio University Hospital
🇯🇵Tokyo, Japan
Yamagata University Hospital
🇯🇵Yamagata, Japan
Inje university Haeundae Paik Hospital
🇰🇷Busan, Korea, Republic of
Pusan National University Hospital
🇰🇷Busan, Korea, Republic of
Keimyung University Dongsan Medical Center
🇰🇷Daegu, Korea, Republic of
Chungnam National University Hospital
🇰🇷Daejeon, Korea, Republic of
National Cancer Center
🇰🇷Goyang-si, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Jeollanam-do, Korea, Republic of
Korea University Anam Hospital
🇰🇷Seoul, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Seoul St Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Yeouido St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Health Pharma Professional Research
🇲🇽Cdmx, Mexico CITY (federal District), Mexico
Inst. Nacional de Cancerologia
🇲🇽Mexico City, Mexico CITY (federal District), Mexico
Hospital General de Mexico
🇲🇽Mexico, Tlaxcala, Mexico
Hospital de Especialidades Centro Medico Nacional La Raza
🇲🇽Mexico City, Mexico
Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny
🇵🇱Brzozów, Poland
Uniwersyteckie Centrum Kliniczne
🇵🇱Gda?sk, Poland
Pratia Onkologia Katowice
🇵🇱Katowice, Poland
?wi?tokrzyskie Centrum Onkologii SPZOZ
🇵🇱Kielce, Poland
PRATIA MCM Kraków
🇵🇱Kraków, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu
🇵🇱Wroc?aw, Poland
Auxilio Mutuo Cancer Center
🇵🇷San Juan, Puerto Rico
Complejo Hospitalario Universitario de Santiago (CHUS)
🇪🇸Santiago de Compostela, LA Coruna, Spain
Hospital Quiron de Madrid
🇪🇸Pozuelo de Alarcon, Madrid, Spain
Clinica Universitaria de Navarra
🇪🇸Pamplona, Navarra, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital General Universitario Gregorio Marañon
🇪🇸Madrid, Spain
Clinica Universidad de Navarra Madrid
🇪🇸Madrid, Spain
Hospital Universitario Virgen del Rocio
🇪🇸Sevilla, Spain
Hospital Clinico Universitario de Valencia
🇪🇸Valencia, Spain
Universitaetsspital Basel
🇨🇭Basel, Switzerland
Chang Gung Medical Foundation - Chai Yi
🇨🇳Chai Yi, Taiwan
Chang Gung Medical Foundation - Kaohsiung;Oncology
🇨🇳Kaoisung, Taiwan
E-Da Cancer Hospital
🇨🇳Kaoshiung, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
Chi-Mei Hospital, Liouying
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
Abdurrahman Yurtarslan Onkoloji Training and Research Hospital
🇹🇷Ankara, Turkey
Ankara Universitesi Tip Fakultesi Hastaneleri - Cebeci Hastanesi
🇹🇷Ankara, Turkey
Istanbul VKV American Hospital
🇹🇷Istanbul, Turkey
Marmara University Pendik Training and Research Hospital
🇹🇷Istanbul, Turkey
Kocaeli Univesity Medical Faculty
🇹🇷Izmit, Turkey
Barnet Hospital
🇬🇧Barnet, United Kingdom
Blackpool Victoria Hospital
🇬🇧Blackpool, United Kingdom
East Kent Hospitals University NHS Foundation Trust
🇬🇧Canterbury, United Kingdom
Royal Devon and Exeter Hospital
🇬🇧Exeter, United Kingdom
Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, United Kingdom
Leeds Teaching Hosp NHS Trust
🇬🇧Leeds, United Kingdom
Leicester Royal Infirmary
🇬🇧Leicester, United Kingdom
University College London Hospitals NHS Foundation Trust - University College Hospital
🇬🇧London, United Kingdom
Guy'S Hospital
🇬🇧London, United Kingdom
Newcastle University
🇬🇧Newcastle, United Kingdom
Nottingham University Hospitals NHS Trust
🇬🇧Nottingham, United Kingdom
Churchill Hospital - Oxford Cancer & Haematology Centre
🇬🇧Oxford, United Kingdom
Southampton General Hospital
🇬🇧Southampton, United Kingdom